Capital Markets Day

RNS Number : 5184S

Yourgene Health PLC

06 November 2019

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Capital Markets Day

Manchester, UK 6 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it held a Capital Markets Day for analysts and institutional investors in London yesterday afternoon.

The Capital Markets Day provided an overview of Company strategy and featured presentations from the senior management team alongside a presentation from a Key Opinion Leader:

Presenters on the day included:

-      Lyn Rees, Chief Executive Officer 

-      Hayden Jeffreys, Chief Operating Officer

-      Barry Hextall, Chief Financial Officer

-      Dr. Stephen Little, Founder and Vice Chair

-      Dr. Matthew C. Forman, Head of Bioinformatics & Software

-      Professor Basky Thilaganathan, Director, Fetal Medicine Unit and Clinical Lead, The SAFE test laboratory

The presentation made at the Capital Markets Day is available on the Company's website to download and a video of the presentation will be made available in due course here:

https://www.yourgene-health.com/investors/company-information/investor-presentations

No new material information was disclosed.

Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing	Tel: [phone] [e-mail]
Stifel Nicolaus Europe Limited (Sole Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison		Tel: [phone]
Walbrook PR Ltd (Media and Investor Relations) Paul McManus / Lianne Cawthorne	Tel: [phone] or [e-mail] Mob: [phone] Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

END

 

 

NRAUGGBCGUPBGWQ